Acta Neurologica Belgica https://doi.org/10.1007/s13760-018-0948-2 LE T TER TO THE EDITOR Tumefactive demyelinating lesions in a patient with multiple sclerosis receiving natalizumab 1,2 3 Abdorreza Naser Moghadasi · Seyed Mohammad Baghbanian Received: 20 March 2018 / Accepted: 22 May 2018 © Belgian Neurological Society 2018 Abbreviations Case presentation MS Multiple sclerosis TDL Tumefactive demyelinating lesions The patient was a 33-year-old woman on treatment with PML Progressive multifocal leukoencephalopathy glatiramer acetate and azathioprine who due to two attacks MOG Anti-Myelin oligodendrocyte glycoprotein within a year, her drug was changed to injection of natali- JCV John Cunningham virus zumab 300 mg per month. Four months after the injection HIV Human immunodeficiency virus of natalizumab, the patient experienced a blurred vision LP Lumbar puncture of the left eye. She did not have any clinical symptoms such as dementia, palsy and sensory disturbance. In brain MRI, two TDLs were observed (Fig. 1a, b). The cervical Introduction and optic nerve MRI was still normal without any gado- linium enhancement. The anti-aquaporin-4 antibody was re- Natalizumab has a positive impact on reducing attacks checked, which was negative. Anti-Myelin oligodendrocyte and can also reduce the incidence of new plaques in mag- glycoprotein (MOG) antibodies were also negative. John netic resonance imaging (MRI) of multiple sclerosis
Acta Neurologica Belgica – Springer Journals
Published: Jun 6, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud